Multiple Sclerosis Treatment Insurance Claim Denied? How to Appeal

A diagnosis of multiple sclerosis (ICD-10: G35) is life-altering. When your insurer then denies coverage for the disease-modifying therapy your neurologist has prescribed, the frustration and fear compound immediately. MS is a chronic, progressive neurological condition — relapsing-remitting (RRMS), primary progressive (PPMS), or secondary progressive (SPMS) — that can cause irreversible disability if not treated promptly and appropriately. Each relapse can leave permanent neurological deficits. Insurance denials for MS disease-modifying therapies (DMTs), infusion treatments, and monitoring are common but highly appealable with the right clinical and legal strategy.

Why Insurers Deny MS Treatment Claims

Step therapy (fail-first) requirements. The most frequent reason for MS DMT denials. Insurers require patients to try and fail on older, lower-efficacy DMTs — interferon-beta agents (Avonex, Betaseron, Rebif, Extavia) or glatiramer acetate (Copaxone) — before approving newer high-efficacy therapies. Your neurologist may recommend a high-efficacy agent as first-line given high disease burden, rapidly evolving RRMS, or specific biomarker profile: ocrelizumab (Ocrevus, also the only FDA-approved therapy for PPMS), natalizumab (Tysabri), alemtuzumab (Lemtrada), ofatumumab (Kesimpta), or cladribine (Mavenclad).

"Not medically necessary" determinations. Insurers assert that a specific DMT is unnecessary, that the patient's disease is "mild," or that a cheaper alternative is equivalent — without the neurological expertise to evaluate the individualized clinical picture your neurologist used to make the recommendation. These determinations are frequently made by reviewers without neurology or MS subspecialty training.

"Experimental or investigational" denials. Certain MS treatment approaches — BTK inhibitors currently in Phase III trials, high-dose cyclophosphamide for aggressive RRMS, or autologous hematopoietic stem cell transplantation (aHSCT) for highly active MS — may be denied as experimental despite use at major MS centers and growing peer-reviewed evidence.

Infusion therapy denials. Ocrelizumab (Ocrevus) and natalizumab (Tysabri) require IV infusion and generate denials around site-of-service (requiring infusion center rather than hospital outpatient infusion suite), concurrent review mid-infusion, or Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization expiration between infusion cycles.

MRI monitoring denials. Regular brain and spinal cord MRI is essential for monitoring MS disease activity, tracking treatment response, and detecting new T2 lesions or gadolinium-enhancing lesions. Insurers sometimes deny MRIs as "too frequent" using criteria that don't reflect National MS Society (NMSS) monitoring recommendations or the FDA labeling requirements for specific DMTs that mandate periodic MRI.

How to Appeal an MS Treatment Denial

Step 1: Document Disease Burden with Objective Measures

Your neurologist should document current disease activity using validated measures: EDSS (Expanded Disability Status Scale) score reflecting current disability level; relapse rate over the past 1–2 years with each relapse dated and documented; MRI lesion burden including T2/FLAIR lesion count, gadolinium-enhancing lesions indicating active inflammation, and year-over-year lesion progression; and any evidence of spinal cord involvement or cognitive decline. High baseline disease activity (multiple relapses, active MRI lesions, rapid disability accumulation) is the strongest argument for initiating high-efficacy DMT without a step therapy requirement.

Step 2: Address Step Therapy Requirements with Clinical Specificity

If the insurer requires trial of interferon-beta or glatiramer acetate first, your neurologist must document specifically why that pathway is clinically inappropriate for you: rapidly evolving relapsing MS (more than 2 relapses in 12 months with MRI activity) that warrants immediate high-efficacy therapy; JC virus antibody positivity affecting natalizumab risk stratification; prior failure on a lower-efficacy DMT in the required class; specific comorbidities or tolerability issues that contraindicate the required step agent; or PPMS diagnosis for which ocrelizumab is the only FDA-approved therapy. Cite your applicable state's step therapy reform statute — more than 30 states have enacted laws requiring exceptions when step therapy is clinically inappropriate.

Step 3: Cite NMSS and AAN Clinical Practice Guidelines

The National Multiple Sclerosis Society (nationalmssociety.org) and the American Academy of Neurology (AAN) publish clinical practice guidance widely accepted as the standard of care for MS management. NMSS endorses individualized DMT selection based on disease activity, risk tolerance, and patient goals — not blanket step therapy protocols. The AAN MS Practice Guideline Update (Neurology, 2018 and subsequent updates) similarly supports high-efficacy first-line therapy in patients with highly active disease. Cite the specific recommendations that apply to your disease profile.

Step 4: Emphasize the Irreversible Risk of Delay

Unlike many conditions where treatment delays cause reversible harm, untreated or undertreated MS causes irreversible neurological damage during periods of active disease. Each relapse has the potential to leave permanent neurological deficits that cannot be recovered through later treatment. Your appeal should explicitly document the risk of permanent neurological harm if treatment is delayed, and request an expedited internal review if the clinical situation is urgent.

Step 5: Request Peer-to-Peer Review

Have your neurologist request a direct peer-to-peer review with the insurer's medical director. A neurologist-to-neurologist or MS specialist-to-neurologist peer conversation is highly effective for MS DMT denials, particularly when you can present EDSS scores, relapse history, and MRI documentation showing high disease activity that clearly supports the recommended therapy.

Step 6: File Internal Appeal and Escalate to External Independent Review: Complete Guide" class="auto-link">External Review

Submit your written appeal within 180 days of denial. Include: neurologist's letter citing NMSS and AAN guidelines; MRI brain and spine reports with lesion burden documentation; EDSS score and relapse history; step therapy analysis and override request citing applicable state statute; documentation of any prior DMT trials and outcomes; and FDA prescribing information for the requested DMT. Request review by a board-certified neurologist with MS subspecialty expertise. If internal appeal fails, file for independent external review specifying MS neurology expertise — external reviewers apply NMSS and FDA standards, not internal insurer policy bulletins.

What to Include in Your Appeal

• Denial letter with specific stated reasons and clinical criteria cited
• Neurologist's letter of medical necessity citing NMSS and AAN guideline recommendations
• ICD-10 code G35 with MS subtype specified (RRMS, PPMS, SPMS) in all clinical documentation
• Current EDSS score and relapse history (frequency, dates, residual deficits)
• Brain and spinal MRI reports showing lesion burden and disease activity
• Step therapy override request with state statute citation and clinical contraindication documentation
• FDA prescribing information for the requested DMT and NMSS clinical guidance supporting its use

Fight Back With ClaimBack

Every delay in MS treatment carries the risk of permanent neurological damage that cannot be undone. An insurance denial is not a clinical judgment — it is an administrative barrier that your neurologist's expertise, NMSS guidelines, and ERISA appeal rights can overcome. ClaimBack generates a professional appeal letter in 3 minutes, citing the specific NMSS recommendations, AAN guidelines, and federal regulations that apply to your MS treatment denial. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal